All News
#EULAR2024 POS0467 - Periodontal disease related tot he development of #RA
ACPA positive and negative pts.
Tooth extraction in CCP positive pts was associated.
Need tooth history in RA. @RheumNow https://t.co/b9Nb3cd0kd
Links:
Bella Mehta bella_mehta ( View Tweet)
Could dogs smell RA? lol...!
Exhaled breath experimental study to diagnose RA?
Volatile organic compounds can detect RA?
#EULAR2024 @RheumNow https://t.co/FiHsZ522In
Links:
Bella Mehta bella_mehta ( View Tweet)
Deep B cell depletion strategies for Drug resistant RA @RheumNow #EULAR2024
for those which dont want to use CAR-T cells / other options.
Maybe used in other diseases. https://t.co/joRhfWaiDs
Links:
Bella Mehta bella_mehta ( View Tweet)
EULAR
OP0041 (2024)
COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
EULAR
OP0092 (2024)
INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
#EULAR2024 highlight from Prof Pitzalis & team- synovial phosphoproteome analysis in late-stage RA identifies signalling pathways assoc with pathotype & response to RTX & TOC
Study highlights active signalling pathways assoc with pathotype & drug response
OP0218 @RheumNow https://t.co/RZMSgj9T6k
Mrinalini Dey DrMiniDey ( View Tweet)
Spatial transcriptomics work highlighted at #EULAR2024 @RheumNow https://t.co/5NvX1PW2tA
Links:
Bella Mehta bella_mehta ( View Tweet)
Basic Science highlights at #EULAR2024 @RheumNow https://t.co/gr3Mysp3f4
Bella Mehta bella_mehta ( View Tweet)
Photos of hands/finger folds for RA disease activity - nice idea, challenges++, but with poor photo quality you’re always struggling.
Telehealth has taught us:
- ideal settings can work, but
- suboptimal inputs inevitably lead to suboptimal results
#EULAR2024 POS0451 @RheumNow https://t.co/fyCQzSl6tB
David Liew drdavidliew ( View Tweet)
Have RA and want to get pregnant? What can you do?
The answer is simple: disease control.
Implementing T2T in RA led to much better fertility. RA therapy is your friend!
#EULAR2024 POS0436 Rotterdam @RheumNow https://t.co/aoxNakMix1
Links:
David Liew drdavidliew ( View Tweet)
OP0007 (2024)
S/C ABA VS ADA H2H COMPARISON ADULTS EARLY, DUAL SEROPOSITIVE RA, +ive FOR SHARED EPITOPE HLA CLASS II RISK ALLELES, & INADEQUATE RESPONSE TO MTX: RESULTS FROM PH3 AMPLIFIED TRIAL shame seropositivity did not translate to an advantage for AbA @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
Another proof (if needed) that controlling DA in RA is a very important preventive measure in RA!
179 pts
ILD newly developed 9.5%
progressed 12.3%
no change 74.9%
improved 4.5%
5.7% in the LDA group 28.0% non-LDA group (p=0.006)
@RheumNow #EULAR2024 POS0408 https://t.co/7DyXr5zdCM
Aurelie Najm AurelieRheumo ( View Tweet)
POS0061 (2024)
INTERCEPTION OF THE DEVELOPMENT OF RA BY 1-YEAR MTX IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RA: 4 YEAR RESULTS OF THE TREAT EARLIER TRIAL MTX reduced development of RA in high risk acpa neg pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
T2T strategy in RA during pregnancy improves time to procreate
Results PreCARA (T2T median DAS28CRP 2.33) vs. PARA median DAS28CRP 3.84)
median TTP 84d vs. 196d
TTP exceeded 12 months in 23% of PreCARA pts compared to 42% in the PARA pts.
@RheumNow #EULAR2024 POS0436 https://t.co/DfgEvvtCwR
Aurelie Najm AurelieRheumo ( View Tweet)
EULAR Abstract Archive
POS0894 (2024)
SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA
Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
Links:
Peter Nash drpnash ( View Tweet)
Frank Buttgereit discusses potential reason for ceiling effect in RA and questions why we don’t use more combination therapy in RA (including low dose of of GC), using the example of Hypertension guidelines
Is long term low dose GC in RA really a desirable option?
@RheumNow… https://t.co/Nc7lldN7Nd https://t.co/63K96uuhKG
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2024 POS0436 Another benefit of T2T to achieve remission by using less NSAIDs, lower GC, earlier use of SFZ, HCQ and TNF-i = shorter Time to Pregnancy from conception in #RA women (median 84 days) vs without pre-counselling & T2T (196 days) @RheumNow https://t.co/2ZpDLmPVt0
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Data form TARA trial Taper in RA remission
Flare free survival at 2 yrs 35%
Risk of flare is similar in ACPA+ & ACPA- RA
Risk of flare is similar if taper TNFi first or csDMARD first
@RheumNow #EULAR2024 POS0405 https://t.co/89gAglHUcw
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2024
@AilsaBosworth1 highlights the programmes available for pts diagnosed with #RA via the @NRAS_UK platform
SMILE-RA and RightStart are great resources for self-management, can highly recommend to all clinicians!
@RheumNow https://t.co/SgAMKkcycE
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
OP0238-HPR: effectiveness of digital patient education programme for RA self-management
Intervention led to improved self-efficacy, w minor improved RA knowledge, #HealthLiteracy & #QoL
➡️such interventions may improve self-management & lower health costs
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
